Wednesday, September 9, 2020 Probiotic Skin Therapy Improves Eczema in Children, Study Suggests Inner elbow of a child with eczema before Roseomonas mucosa therapy (left) and after four months of treatment (right). An experimental treatment for eczema that aims to modify the skin microbiome safely reduced disease severity and increased quality of life for children as young as 3 years of age, a NIAID study has found. These improvements persisted for up to eight months after treatment stopped. The results, reported today in Science Translational Medicine, support further research to assess the safety and effectiveness of this investigational treatment. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107